India CRO Market: How Is Infectious Disease Segment Growing in Indian CRO?

The India CRO Market is seeing infectious disease segment grow in Indian CRO commanding approximately 15-18% market share as India faces high infectious disease burden including tuberculosis affecting 70 million patients, malaria affecting 20 million patients, and dengue affecting 10 million patients requiring extensive clinical research for new drug development, multiple infectious disease therapies requiring CRO services, expanding biotechnology infectious disease pipeline, and regulatory support for innovative treatments creating substantial CRO demand.

Infectious disease represents significant Indian CRO therapeutic area with 100+ ongoing clinical trials in India. India has 70 million tuberculosis patients representing 5% of population and 27% of global tuberculosis cases. India has 20 million malaria patients and 10 million dengue patients. High infectious disease prevalence due to tropical climate, population density, and sanitation challenges creates enormous CRO demand. CDSCO and WHO approved 30+ infectious disease therapies requiring CRO services.

Infectious disease trial categories include tuberculosis trials representing 40% (40 trials), malaria trials representing 25% (25 trials), dengue trials representing 15% (15 trials), and other infectious disease trials representing 20% (20 trials). Tuberculosis trials dominate including trials for new antibiotics and combination therapies. Malaria trials address antimalarial drugs. Dengue trials develop vaccines and treatments.

Indian CROs provide comprehensive infectious disease services including patient recruitment targeting infected patients, data management for complex infectious disease data, regulatory submissions for CDSCO and WHO approvals, and trial monitoring ensuring patient safety. Quark conducts 25+ infectious disease trials annually. Elicious conducts 20+ trials annually. IQVIA India conducts 15+ trials annually. Other CROs conduct 40+ trials collectively.

Infectious disease Indian CRO market growth driven by high infectious disease burden with 100 million total patients, expanding therapy approvals, vaccine development requiring CRO services, and regulatory support accelerating approvals.

Infectious disease Indian CRO revenue represents USD 270-324 million annually (15-18% of USD 1.8 billion market). Market projected to reach USD 630-756 million by 2033 (15% of USD 4.2 billion).

FAQs

Q1: Why is infectious disease segment growing in Indian CRO with 15-18% market share? Infectious disease grows with 100+ ongoing Indian trials (40 tuberculosis, 25 malaria, 15 dengue, 20 other) due to India having 70 million tuberculosis patients (27% of global cases), 20 million malaria patients, and 10 million dengue patients, 30+ CDSCO/WHO-approved therapies requiring CRO services, and vaccine development, generating USD 270-324 million revenue (15-18%).

Q2: What infectious disease CRO services are provided? Patient recruitment, data management, CDSCO/WHO regulatory submissions, and trial monitoring with Quark conducting 25+ trials, Elicious 20+ trials, and IQVIA India 15+ trials annually.

#IndiaCRO #InfectiousDisease #ClinicalTrials #Tuberculosis #Malaria #Dengue #CRO #CDSCO #India